NASDAQ:CLSD Clearside Biomedical (CLSD) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free CLSD Stock Alerts $1.23 -0.02 (-1.60%) (As of 05/13/2024 ET) Add Compare Share Share Today's Range$1.21▼$1.2750-Day Range$1.15▼$2.0252-Week Range$0.65▼$2.12Volume109,223 shsAverage Volume312,912 shsMarket Capitalization$91.91 millionP/E RatioN/ADividend YieldN/APrice Target$4.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Clearside Biomedical alerts: Email Address Clearside Biomedical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside265.9% Upside$4.50 Price TargetShort InterestHealthy0.45% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.13Based on 19 Articles This WeekInsider TradingAcquiring Shares$56,388 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.56) to ($0.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.51 out of 5 starsMedical Sector486th out of 925 stocksPharmaceutical Preparations Industry224th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingClearside Biomedical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageClearside Biomedical has only been the subject of 4 research reports in the past 90 days.Read more about Clearside Biomedical's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.45% of the outstanding shares of Clearside Biomedical have been sold short.Short Interest Ratio / Days to CoverClearside Biomedical has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clearside Biomedical has recently increased by 27.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldClearside Biomedical does not currently pay a dividend.Dividend GrowthClearside Biomedical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLSD. Previous Next 2.9 News and Social Media Coverage News SentimentClearside Biomedical has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Clearside Biomedical this week, compared to 1 article on an average week.Search Interest11 people have searched for CLSD on MarketBeat in the last 30 days. This is an increase of 120% compared to the previous 30 days.MarketBeat Follows5 people have added Clearside Biomedical to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Clearside Biomedical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $56,388.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 9.80% of the stock of Clearside Biomedical is held by insiders.Percentage Held by InstitutionsOnly 18.75% of the stock of Clearside Biomedical is held by institutions.Read more about Clearside Biomedical's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Clearside Biomedical are expected to grow in the coming year, from ($0.56) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clearside Biomedical is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clearside Biomedical is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Clearside Biomedical's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Clearside Biomedical Stock (NASDAQ:CLSD)Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Read More CLSD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLSD Stock News HeadlinesMay 7, 2024 | insidertrades.com3 Penny Stocks That Insiders Are Buying (CLSD)May 13 at 10:52 AM | markets.businessinsider.comBuy Rating for Clearside Biomedical Amid Promising CLS-AX Trial Progress and Sufficient Cash RunwayMay 12 at 2:52 AM | americanbankingnews.comStockNews.com Downgrades Clearside Biomedical (NASDAQ:CLSD) to SellMay 10 at 6:50 PM | markets.businessinsider.comBuy Rating Affirmed: Clearside Biomedical’s Promising Phase 2b Odyssey Trial and Strategic CMO Hire Signal Strong OutlookMay 10 at 6:50 PM | finance.yahoo.comClearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2024 Earnings Call TranscriptMay 10 at 6:50 PM | finance.yahoo.comQ1 2024 Clearside Biomedical Inc Earnings CallMay 10 at 4:42 AM | markets.businessinsider.comBuy Rating on Clearside Biomedical: Anticipating ODYSSEY Trial Success and Market Growth PotentialMay 9, 2024 | globenewswire.comClearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | globenewswire.comClearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences ConferenceApril 30, 2024 | globenewswire.comClearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024April 21, 2024 | seekingalpha.comCLSD Clearside Biomedical, Inc.April 16, 2024 | globenewswire.comClearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of DirectorsApril 2, 2024 | globenewswire.comClearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 18, 2024 | globenewswire.comClearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical OfficerMarch 14, 2024 | markets.businessinsider.comClearside Biomedical: Strong Buy Rating on Robust Financials and Clinical Trial ProgressMarch 14, 2024 | finance.yahoo.comClearside Biomedical Full Year 2023 Earnings: Revenues Beat Expectations, EPS In LineMarch 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Clearside Biomedical on Innovative Treatments and Strong FinancialsMarch 13, 2024 | finance.yahoo.comClearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call TranscriptMarch 12, 2024 | benzinga.comClearside Biomedical: Q4 Earnings InsightsMarch 12, 2024 | finance.yahoo.comClearside Biomedical Inc (CLSD) Reports Significant Licensing Revenue Growth in Q4 and Full ...March 12, 2024 | globenewswire.comClearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 11, 2024 | benzinga.comPreview: Clearside Biomedical's EarningsMarch 1, 2024 | finance.yahoo.comClearside Biomedical, Inc. (CLSD)February 29, 2024 | globenewswire.comClearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024February 25, 2024 | investorplace.com7 Biotech Penny Stocks on the Verge of Clinical Trial VictorySee More Headlines Receive CLSD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/13/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CLSD CUSIPN/A CIK1539029 Webwww.clearsidebio.com Phone(678) 270-3631Fax678-270-4033Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$4.50 High Stock Price Target$5.00 Low Stock Price Target$4.00 Potential Upside/Downside+289.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,490,000.00 Net Margins-413.73% Pretax Margin-394.91% Return on EquityN/A Return on Assets-97.47% Debt Debt-to-Equity RatioN/A Current Ratio4.42 Quick Ratio4.42 Sales & Book Value Annual Sales$8.23 million Price / Sales11.08 Cash FlowN/A Price / Cash FlowN/A Book Value($0.25) per share Price / Book-4.88Miscellaneous Outstanding Shares74,720,000Free Float67,398,000Market Cap$91.16 million OptionableOptionable Beta2.35 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. George M. Lasezkay J.D. (Age 72)Pharm.D., Pharma.D., President, CEO & Director Comp: $816.4kMr. Charles A. Deignan (Age 60)Chief Financial Officer Comp: $536.95kDr. Thomas A. Ciulla M.B.A. (Age 59)M.D., Chairman of Scientific Advisory Board Comp: $597.21kMs. Jenny R. Kobin (Age 57)Head of Investor Relations Mr. Rick McElhenyVice President of Corporate DevelopmentMr. Rafael V. Andino (Age 59)Senior Vice President of Engineering & Manufacturing Ms. Susan L. Coultas Ph.D.Chief Clinical OfficerDr. Ngai Hang Chong M.B.A.M.D., Chief Medical OfficerMr. Leslie B. Zacks (Age 55)Secretary More ExecutivesKey CompetitorsEton PharmaceuticalsNASDAQ:ETONAclaris TherapeuticsNASDAQ:ACRSOramed PharmaceuticalsNASDAQ:ORMPAnixa BiosciencesNASDAQ:ANIXMilestone PharmaceuticalsNASDAQ:MISTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 314,480 shares on 5/10/2024Ownership: 3.333%SG Americas Securities LLCBought 32,270 shares on 5/7/2024Ownership: 0.043%Rosalind Advisors Inc.Bought 2,592,593 shares on 4/25/2024Ownership: 3.470%Anthony S GibneyBought 6,710 shares on 4/17/2024Total: $8,387.50 ($1.25/share)International Assets Investment Management LLCBought 36,000 shares on 4/11/2024Ownership: 0.048%View All Insider TransactionsView All Institutional Transactions CLSD Stock Analysis - Frequently Asked Questions Should I buy or sell Clearside Biomedical stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLSD shares. View CLSD analyst ratings or view top-rated stocks. What is Clearside Biomedical's stock price target for 2024? 4 brokers have issued 1-year price targets for Clearside Biomedical's shares. Their CLSD share price targets range from $4.00 to $5.00. On average, they anticipate the company's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 265.9% from the stock's current price. View analysts price targets for CLSD or view top-rated stocks among Wall Street analysts. How have CLSD shares performed in 2024? Clearside Biomedical's stock was trading at $1.17 at the beginning of the year. Since then, CLSD stock has increased by 5.1% and is now trading at $1.23. View the best growth stocks for 2024 here. When is Clearside Biomedical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our CLSD earnings forecast. How were Clearside Biomedical's earnings last quarter? Clearside Biomedical, Inc. (NASDAQ:CLSD) announced its quarterly earnings data on Thursday, May, 9th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.03. The firm had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.98 million. During the same period in the previous year, the firm posted ($0.15) earnings per share. What other stocks do shareholders of Clearside Biomedical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Melinta Therapeutics (MLNT), Organigram (OGI), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Miragen Therapeutics (MGEN) and When did Clearside Biomedical IPO? Clearside Biomedical (CLSD) raised $50 million in an IPO on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager. Who are Clearside Biomedical's major shareholders? Clearside Biomedical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Rosalind Advisors Inc. (3.47%), Vanguard Group Inc. (3.33%), International Assets Investment Management LLC (0.05%), SG Americas Securities LLC (0.04%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Anthony S Gibney, Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, Nancy J Hutson, Ngai Hang Victor Chong, Richard T Burke and Thomas Ciulla. View institutional ownership trends. How do I buy shares of Clearside Biomedical? Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CLSD) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
